A multicenter randomized controlled trial published in Diabetologia on November 14, 2026, evaluated whether smart insulin pens (SIPs) with integrated bolus calculators offer additional glycemic benefits over tracking-only connected insulin pens (CIPs).Connected insulin pens have emerged as useful tools for adults managing diabetes with multiple daily insulin injections (MDI). While tracking-only devices record injection information, the additional clinical benefit of integrating bolus calculator functionality has remained uncertain. Researchers investigated whether this feature could improve glycemic control, insulin dosing behavior, and treatment safety.
Randomized Trial Design The open-label trial was conducted across nine medical centers in South Korea and enrolled 120 adults aged 19β74 years with Type 1 or Type 2 diabetes receiving MDI therapy. Participants had baseline HbA1c levelsβ¦